2-ethoxycarbonyl-4-methylpentanoic acid | 2985-36-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-ethoxycarbonyl-4-methylpentanoic acid
• 英文别名: 2-(methylpropyl)malonate half ethyl ester；2(R,S)-isobutylmalonic acid ethyl ester；2-isobutylmalonic acid monoethyl ester；2-ethoxycarbonyl-4-methylvaleric acid；isobutyl-malonic acid monoethyl ester；Isobutyl-malonsaeure-monoaethylester
• CAS: 2985-36-6
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: QLDRWYAZMWIZFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  92-95 °C(Press: 0.1 Torr)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-ethoxycarbonyl-4-methylpentanoic acid 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 46.0h， 生成 (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-(aminomethylcarbamoyl)-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid
  参考文献：
  名称：

  Partially Modified Retro-Inverso Pseudopeptides as Non-natural Ligands for the Human Class I Histocompatibility Molecule HLA-A2

  摘要：

  Syntheses of a series of partially modified retro-inverso analogues of the antigenic peptide M58-66 derived from the influenza virus matrix protein are reported. The retro-inverso modification Psi(NH-CO) was obtained by replacement of two successive amino acid residues with a 2-substituted malonate derivative and gem-diaminoalkyl residue. The resulting compounds 1-8 were tested for their binding to the human histocompatibility class I molecule HLA-A2 in an assembly assay using lysates of peptide transporter-deficient cells T2. Specific peptide-dependent HLA-A2 assembly was revealed by an enzyme-linked immunosorbent assay. Significant HLA-A2 assembly was detected in the presence of analogues [gGly(58)-(S)mLeu(59)]-M58-66 (1a), [gGly(61)-(R,S)mPhe(62)]M58-66 (4), [gVal(63)-(R,S)mPhe(64)]M58-66 (6), and [gPhe(64)-(R,S)mAla(65)]M58-66 (7). The introduction of the retro-inverso modification between P2-P3, P3-P4, P5-P6, and P8-P9 (compounds 2, 3, 5, and 8, respectively) however led to a dramatic reduction in peptide binding to HLA-A2. Interestingly, compound 1a which contains modification between P1-P2 was found to be the most potent analogue, being able to retain the original HLA-A2 binding profile of the parent peptide M58-66. Taken together, these results and recent binding data obtained in the context of murine MHC class I molecule H-2K(d) suggest that the incorporation of peptide bond surrogates in MHC class I-restricted epitopes is a useful approach to design molecules having both increased stability and high MHC-binding capacity. Depending on their agonist or antagonist effects at the T-cell receptor, such non-natural MHC ligands are likely to find many applications in the development of peptide-based vaccines or as potential therapeutic agents in the treatment of allergies and autoimmune diseases.

  DOI：

  10.1021/jm9509511
• 作为产物：
  描述：

  丙二酸二乙酯 在 sodium ethanolate 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-ethoxycarbonyl-4-methylpentanoic acid
  参考文献：
  名称：

  Functional examination of novel kisspeptin phosphinic peptides

  摘要：

  吻肽作用于其同源的 G 蛋白偶联受体--吻肽受体，在抑制癌细胞转移和调节生殖系统方面发挥着重要作用，因此对治疗干预具有重要意义。所有原生功能性人类吻肽（吻肽素-54、吻肽素-14 和吻肽素-13）的 C 端（45-54）都含有吻肽素-10 的 10 个氨基酸。然而，它们会被基质金属蛋白酶（MMPs）通过裂解甘氨酸51 和亮氨酸52 之间的肽键而迅速失活，这限制了它们的临床应用。开发抗 MMP 的吻肽类似物可提供更好的治疗效果。本研究设计并合成了两种吻肽（kisspeptin phosphinic peptides），评估了它们通过吻肽（kisspeptin）受体诱导ERK1/2磷酸化的能力及其对与癌症转移相关的MMP-2和MMP-9的抑制作用。结果表明，其中一种类似物--膦酰基吻肽素 R 异构体（PKPR）不仅具有吻肽素受体拮抗活性，还具有抑制 MMP-2 的活性，这表明 PKPR 可作为进一步开发用于治疗的吻肽素类似物的先导。

  DOI：

  10.1371/journal.pone.0195089

文献信息

• [EN] DUAL-ACTING ANTIHYPERTENSIVE AGENTS<br/>[FR] AGENTS ANTIHYPERTENSIFS À DOUBLE ACTION
  申请人：THERAVANCE INC

  公开号：WO2009035543A1

  公开（公告）日：2009-03-19

  The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下公式的化合物：(I) 其中：Ar、r、R3、Z、X和R5-7按说明书定义，或其药用可接受盐。这些化合物具有AT1受体拮抗活性和中性内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Utilization of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold in the design of potent inhibitors of serine proteases: SAR studies using carboxylates
  作者：Rongze Kuang、Jeffrey B. Epp、Sumei Ruan、Lee S. Chong、Radhika Venkataraman、Juan Tu、Shu He、Tien M. Truong、William C. Groutas

  DOI：10.1016/s0968-0896(00)00038-9

  日期：2000.5

  A series of carboxylate derivatives based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds has been synthesized and the inhibitory profile of these compounds toward human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3) was then determined. Most of the compounds were found to be potent, time-dependent inhibitors of elastase, with some

  合成了一系列基于1,2,5-噻二唑烷酮-3-1,1二氧化和异噻唑烷-3-3-1的二羧酸骨架的羧酸衍生物，这些化合物对人白细胞弹性蛋白酶（HLE）的抑制作用），然后测定组织蛋白酶G（Cat G）和蛋白酶3（PR 3）。发现大多数化合物是弹性蛋白酶的有效时间依赖性抑制剂，其中某些化合物的k（inact）/ K1值高达4,928,300 M（-1）s（-1）。发现基于1,2,5-噻二唑啉-3--1,1二氧化平台的羧酸衍生物的抑制能力受pKa和离去基团固有结构的影响。发现正确选择主要特异性组（R（I））可以导致对HLE的选择性抑制高于Cat G，但是，那些抑制HLE的化合物也抑制PR 3，尽管效率较低。这些化合物的可预测结合方式表明，在紧密相关的丝氨酸蛋白酶中，可以通过利用它们的S'亚位点的细微差别来形成特定丝氨酸蛋白酶的高选择性抑制剂。这项研究还表明，在存在抑制剂17的情况下，弹性蛋白酶对弹性蛋白的降解作用可以消除。
• Dual-acting benzoimidazole antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080318951A1

  公开（公告）日：2008-12-25

  The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R 2-3 and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及具有以下结构的化合物： 其中：Ar、r、n、X、R 2-3 和R 5-7 如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT 1 受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：Allegretti Paul

  公开号：US20090270473A1

  公开（公告）日：2009-10-29

  The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及具有以下式的化合物：其中：Q、W、Y、Z、r 和 Ar 如规范中所定义，并其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。